Neuralstem: Top-Line Results Of Phase 2 ALS Trial Are Compelling

Compelling top-line results from Neuralstem NSI-566 ALS Phase 2 study continue to increase confidence of providing a meaningful therapeutic benefit to ALS patients. Findings from the Phase 2 study support a hypothesis and method to identify responders to drug therapy - which will be tested by Neuralstem in a follow-up larger placebo-controlled study.

http://ift.tt/1x1GCGt